Navigation Links
China Biologic Products Announces Approval for Setting Up a New Plasma Collection Station in Pu Bei County, Guangxi Province
Date:6/30/2008

TAIAN CITY, Shandong, China, June 30 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("CBP," or "the Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that the Company received the approval from the Guangxi Province Bureau of Health, to set up a new plasma collection station in Pu Bei County, Guangxi Province.

The new plasma collection station will be located in the Centralized Industry Zone of Pu Bei County and when it becomes operational, it will replace CBP's existing Fang Cheng Plasma Collection Station ("Fang Cheng"). The Company's management decided to relocate the Fang Cheng Plasma Collection Station to a more strategic location to increase collection volumes. During the construction period, the existing Fang Cheng Plasma Station will still continue with its normal operations. With the approval of the new location, the Company hopes to expand its coverage area to secure higher collection volumes in the future.

"Since we received approval to relocate Fang Cheng earlier this year, we inspected several relocation sites and settled on Pu Bei County as the best choice," said Mr. Chao Ming Zhao, the Company's CEO. "We are confident that the new plasma collection station will help to greatly expand our plasma supply once it is established."

About China Biologic Products, Inc.

Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the "Company"), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the effect of relocating its plasma collection station, the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:

Mr. Y. Tristan Kuo

CFO

China Biologic Products, Inc.

Tel: +86-538- 6202206

Email: IR@chinabiologic.com

Web: http://www.chinabiologic.com

Investor Relations Contact:

Mr. Crocker Coulson

President

CCG Investor Relations

Tel: +1-646-213-1915 (NY office)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Clean Energy Updates Business Outlook
2. China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company
3. Kiwa Bio-Tech Receives Authorization From the Ministry of Commerce of the Peoples Republic of China to Wholesale Other Fertilizer Manufacturers Products
4. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
5. Beike Biotech Opens Comprehensive Stem Cell Storage and Processing Facility in China
6. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
7. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
8. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
9. China Sun Group High-Tech Co. Completes Share Exchange to Create 100% Ownership in DLX Subsidiary
10. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
11. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... ... Limfinity® Cloud, RURO has enhanced the platform to accommodate increasingly complex and ... rapid data searching, and more. In addition to these improvements, the latest ...
(Date:1/11/2017)... NEW YORK , Jan. 11, 2017  Brian ... surgeon, and founder of Blue Horizon International (BHI), will ... in Davos from January 17-20, ... the global conference. The theme of this ... of the program,s 400 sessions will address strategies for ...
(Date:1/11/2017)... ... January 11, 2017 , ... For many fledging ... navigating the challenges young businesses face. With the second installment of Quorum’s newest ... of Geoff DiMasi, Founder and Principal of interactive design agency, P’unk Ave. ...
(Date:1/11/2017)... 2017 AnaptysBio, Inc., a clinical-stage biotechnology ... unmet medical needs in inflammation, today announced the ... financial officer.  Mr. Piscitelli will play a key ... overseeing the company,s accounting and SEC reporting functions. ... Dominic to the senior management team at AnaptysBio," ...
Breaking Biology Technology:
(Date:12/15/2016)... Dec. 15, 2016  There is much more to ... starting the engine. Continental will demonstrate the intelligence of ... Vegas . Through the combination of the keyless ... and biometric elements, the international technology company is opening ... and authentication. "The integration of biometric elements ...
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
Breaking Biology News(10 mins):